Table 3.
Antibody/factor | Adjusted geometric mean ratio (95% CI)1 | p value |
---|---|---|
Anti-Rv1733c antibodies in males | ||
Uninfected | 1 | |
LTBI | 0.670 (0.292–1.538) | 0.345 |
APTB | 1.041 (0.636–1.704) | 0.873 |
Anti-Rv1733c antibodies in females | ||
Uninfected | 1 | |
LTBI | 1.812 (1.105–2.973) | 0.019 |
APTB | 1.718 (0.877–3.369) | 0.115 |
Anti-Rv0081 antibodies in males | ||
Uninfected | 1 | |
LTBI | 0.631 (0.300–1.331) | 0.227 |
APTB | 1.183 (0.674–2.075) | 0.558 |
Anti-Rv0081 antibodies in females | ||
Uninfected | 1 | |
LTBI | 2.229 (0.833–5.966) | 0.111 |
APTB | 2.484 (0.948–6.505) | 0.064 |
LTBI = latent tuberculosis infection and APTB = active pulmonary tuberculosis.
1Regression analyses were performed with bootstrap confidence intervals generated from 1000 replicate samples of data. The data was from 29 uninfected males, 21 males with LTBI, 62 males with active PTB, 39 uninfected females, 41 females with LTBI, and 43 females with APTB. The p value for interaction was 0.06 for Rv1733c and 0.04 for Rv0081. Adjusting was done for age and HIV infection status. Analysis was performed on log transformed values and back-transformed to provide geometric mean ratios.